Stephen Davis - Oct 15, 2021 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Oct 15, 2021
Transactions value $
-$51,586
Form type
4
Date filed
10/19/2021, 05:30 PM
Previous filing
Jul 7, 2021
Next filing
Dec 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +5.94K +11.89% 55.9K Oct 15, 2021 Direct F1, F2
transaction ACAD Common Stock Sale -$51.6K -2.96K -5.3% $17.41 52.9K Oct 18, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -5.94K -50% $0.00 5.94K Oct 15, 2021 Common Stock 5.94K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 619 shares of the Issuer's common stock acquired by the reporting person on May 14, 2021 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 The restricted stock units vest in four equal annual installments beginning 10/15/19.